Panel Discussion: Differentiating Next-Gen Oligonucleotides for CNS Therapeutics Safety, Stability & Competitive Advantage
- Discussing safety profiles, stability and translational outcomes across different oligo subtypes including ASO’s, siRNA, saRNA, aptamers and more
- Comparative safety and toxicity considerations across subtypes including off target effects, immunogenicity and long-term durability
- Industry perspective on room for innovation and strategies to stand out in a crowded therapeutic landscape
- What differentiates next-generation modalities and how biopharma can differentiate themselves in an increasingly competitive space